Adaptimmune Therapeutics (ADAP)
(Delayed Data from NSDQ)
$1.58 USD
0.00 (0.00%)
Updated Mar 28, 2024 04:00 PM ET
After-Market: $1.57 -0.01 (-0.63%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Price, Consensus and EPS Surprise
ADAP 1.58 0.00(0.00%)
Will ADAP be a Portfolio Killer in March?
Zacks Investment Research is releasing its prediction for ADAP based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ADAP
Adaptimmune Therapeutics PLC (ADAP) Stock Moves -1.24%: What You Should Know
Adaptimmune (ADAP) Surges More Than 80% in a Month: Here's Why
ADAP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Adaptimmune (ADAP) Rises as GSK Transfers T-Cell Therapy IND
Adaptimmune Therapeutics PLC (ADAP) Loses -28.34% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Adaptimmune Therapeutics PLC (ADAP) Surpasses Market Returns: Some Facts Worth Knowing
Other News for ADAP
Adaptimmune management to meet with Mizuho
Adaptimmune management to meet with Mizuho
Analysts Offer Insights on Healthcare Companies: Ocular Therapeutix (OCUL), Adaptimmune Therapeutics (ADAP) and Arcutis Biotherapeutics (ARQT)
Analysts Offer Insights on Healthcare Companies: Adaptimmune Therapeutics (ADAP), Elevation Oncology (ELEV) and AC Immune SA (ACIU)
Why Marvell Technology Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session